Treatment transition estimates.

* Estimates from Kanwal 2005 [8].
† Initial therapy is 12 months (48 weeks) of therapy.
‡ Estimates calculated by the author, based on the assumption that the natural progression rates of chronic hepatitis B are reduced by antiviral therapy. Estimates derived from natural history estimate similar to Kanwal’s assumption of no progression of disease in HBeAg seroconversion, we assume no progression of disease in case HBV DNA is undetectable by PCR. In the papers from Chang and Lai full suppression of HBV DNA was observed in 80% with a high resistance profile drug, and 90% with a low resistance profile drug. We took these percentages for our calculations [18,19].
§ Estimates for Lamivudine resistance from Lai et al. And Moskovitz et al. [19,20].
|| Estimates for Entecavir from Chang et al. 2006, Lai et al. 2006 and Colonno 2007, [18,19,25] and resistance from Colonno et al. 2006, Colonno et al. 2007 and Tenny et al. 2009. [24–26].
¶ Adefovir salvage resistance estimates from Lee et al., Chen et al. And Yeon et al. [21–23].
** Estimates for tenofovir from Heathcote et al. 2011 [31].
†† Tenofovir salvage scenario estimates from van Bommel et al., Reijnders et al., Ke et al., Gordom et al., Patterson et al., Lee et al. [32–37].
‡‡ Estimates based on reduction of progression rates by nucleoside analogue therapy of 50% [16].
Treatment transition estimates.